$ETON +35% premarket on strong Q2! Record revenue, margin expansion Raised full-year guidance Acquisitions of ASN-001 & IMPAVIDO HEMANGEOL relaunch beating expectations @EtonPharma #ETON #Earnings #Biotech NOT FINANCIAL ADVICE. DYOR